Adaptimmune Therapeutics plc (NASDAQ:ADAP) Given Consensus Rating of “Moderate Buy” by Brokerages

Adaptimmune Therapeutics plc (NASDAQ:ADAP) has received an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $1.93.

Several analysts have recently issued reports on ADAP shares. Wells Fargo & Company reduced their target price on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating for the company in a research note on Friday, March 21st. Guggenheim cut their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a “buy” rating on the stock in a report on Wednesday. Scotiabank decreased their price objective on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a research note on Friday, March 21st. Finally, StockNews.com assumed coverage on Adaptimmune Therapeutics in a research note on Friday, March 21st. They issued a “buy” rating on the stock.

Adaptimmune Therapeutics Price Performance

ADAP stock opened at $0.22 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The business has a 50-day simple moving average of $0.51 and a two-hundred day simple moving average of $0.68. The company has a market capitalization of $56.29 million, a P/E ratio of -1.00 and a beta of 2.52. Adaptimmune Therapeutics has a 52-week low of $0.22 and a 52-week high of $1.65.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative net margin of 25.43% and a negative return on equity of 74.15%. The company had revenue of $3.22 million for the quarter, compared to analysts’ expectations of $16.56 million. Research analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADAP. Invesco Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 82.0% in the 4th quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 28,526 shares during the period. Two Sigma Advisers LP increased its position in Adaptimmune Therapeutics by 492.0% in the fourth quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock worth $38,000 after buying an additional 58,787 shares during the last quarter. Two Sigma Investments LP increased its position in Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company’s stock worth $41,000 after buying an additional 19,146 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of Adaptimmune Therapeutics in the third quarter valued at $95,000. Finally, Virtu Financial LLC lifted its position in shares of Adaptimmune Therapeutics by 27.5% during the 3rd quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 21,769 shares during the last quarter. 31.37% of the stock is currently owned by hedge funds and other institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.